New drugs for acute and chronic kidney disease
About the Company
Arch Biopartners is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD).
Arch’s portfolio targets common types of AKI and CKD that affect millions of patients worldwide and lack effective treatment options. The portfolio features three distinct drug programs:
- CKD platform targeting IL-32 – a pre-clinical program based on a newly discovered mechanism of action directly implicated in the progression of chronic diabetic kidney disease (DKD), the leading cause of kidney failure worldwide.
- LSALT peptide – a first-in-class DPEP1 inhibitor in Phase II trials for preventing cardiac surgery–associated acute kidney injury (CS-AKI).
- Cilastatin – a repurposed drug in Phase II trials for preventing toxin-induced kidney damage.
The CKD program builds on the discovery of interleukin-32 (IL-32), a non-classical cytokine driving tubular injury, inflammation, and fibrosis in diabetic kidney disease. This approach extends Arch’s expertise in nephrology and inflammation biology, while LSALT peptide and cilastatin anchor the Company’s AKI pipeline with the potential to improve outcomes for patients facing inflammation- and toxin-induced kidney injury.
Meeting a critical unmet need
Chronic and acute kidney diseases affect millions of patients worldwide but remain areas with few effective treatment options. Arch’s portfolio of distinct, mechanism-based drug programs is designed to close this gap, targeting serious unmet needs in kidney care across both chronic and acute indications.
Arch Biopartners is led by a team of scientists, executives, and advisors with deep experience in kidney disease, inflammation biology, pharmaceuticals, biotechnology, and corporate finance.
Science and Research Team
Arch’s scientific leadership brings expertise in kidney disease and inflammation, advancing discoveries from the lab to the clinic.
- Dr. Daniel Muruve, Chief Science Officer and Co-Founder, leads the Company’s clinical and translational research, with internationally recognized expertise in nephrology and inflammation.
- Leading investigators from the University of Calgary discovered the dipeptidase-1 (DPEP1) pathway and LSALT Peptide, establishing a first-in-class approach to prevent inflammation-driven kidney injury.
- The addition of Dr. Justin Chun as Principal Scientist marks Arch’s expansion into chronic kidney disease (CKD), advancing a breakthrough platform targeting IL-32 in diabetic CKD.
Executive, Board, and Advisors
- Executives and Founders, CEO Richard Muruve, CSO Dr. Daniel Muruve MD, and CFO Andrew Bishop form the management team.
- The Board of Directors, includes a group of key directors and strategic advisors supporting the Company’s growth and development.
Find key investor information in the Arch Biopartners Investor Hub.
While you’re there, please subscribe to receive the latest investor news and science alerts from the company.
- Stock Performance – Information about ARCH.V and ACHFF with historical and current price data (15 min delay)
- Press Releases – All the company’s news releases, material disclosures and alerts are provided in a complete archive for browsing and research
- Reports and Filings – Management’s Discussion and Analysis, Management’s Information Circulars, Financials and other SEDAR filings are available for download
- Investor Information – Auditor, Transfer Agent, Investor Relations Contact information
